

CLAIMS

1. A stable pharmaceutical composition which comprises a pharmaceutical formulation with an amorphous active substance wherein the pharmaceutical formulation is packed into for gas exchange non-permeable package with packaging carried out in an inert gas atmosphere.
2. The stable pharmaceutical composition according to Claim 1 wherein the amorphous active substance is atorvastatin calcium.
3. The stable pharmaceutical composition according to Claim 1 wherein for gas exchange non-permeable package is Al/Al blister, Al-polychloro-3-fluoroethylene homopolymer/PVC laminate blister or bottle.
4. The stable pharmaceutical composition according to Claim 3 wherein for gas exchange non-permeable package is the Al/Al blister.
5. The stable pharmaceutical composition according to Claim 1 wherein an inert gas is nitrogen or argon.
6. The stable pharmaceutical composition according to Claim 5 wherein the inert gas is nitrogen.
7. The stable pharmaceutical composition according to Claim 1 wherein the pharmaceutical composition is prepared in the form of tablets, orally dispersible pharmaceutical formulations, capsules, pellets or granulate.
8. A stable pharmaceutical formulation comprising an amorphous active substance and pharmaceutically acceptable excipients which is stored in an inert atmosphere.

9. The stable pharmaceutical formulation according to Claim 8 wherein the amorphous active substance is atorvastatin calcium.
10. The stable pharmaceutical formulation according to Claim 8 wherein the gas for maintenance of an inert atmosphere is nitrogen or argon.
11. The stable pharmaceutical formulation according to Claim 10 wherein the gas for maintenance of an inert atmosphere is nitrogen.
12. The stable pharmaceutical formulation according to Claim 8 which is prepared in the form of tablets, orally dispersible pharmaceutical formulations, capsules, pellets or granulate.
13. The stable pharmaceutical formulation according to Claim 8 which is stored into for gas non-permeable package such as Al/Al blister, Al-polychloro-3-fluoroethylene homopolymer/PVC laminate blister or bottle.
14. The stable pharmaceutical formulation according to Claim 13 wherein for gas non-permeable package is the Al/Al blister.
15. A stable amorphous active substance which is stored in an inert atmosphere.
16. The stable amorphous substance according to Claim 15 wherein the amorphous active substance is atorvastatin calcium.
17. The stable amorphous active substance according to Claim 15 wherein the gas for maintenance of an inert atmosphere is nitrogen or argon.
18. The stable amorphous active substance, according to Claim 15 wherein the gas for maintenance of an inert atmosphere is nitrogen.

19. The stable amorphous active substance, according to Claim 15 wherein the active substance is stored into for gas exchange non-permeable packaging such as a metal container, glass container, for gas non-permeable plastic bag or for gas non-permeable plastic container.
20. The stable amorphous active substance according to Claim 19 wherein for the exchange non-permeable packaging is the plastic bag.
21. A method of stabilization of the pharmaceutical composition comprising the pharmaceutical formulation with the amorphous active substance wherein the pharmaceutical formulation is packed into for gas exchange non-permeable packaging and the packaging procedure is carried out in an inert gas atmosphere.
22. The method of stabilization of the pharmaceutical composition according to Claim 21 wherein the amorphous active substance is atorvastatin calcium.
23. The method of stabilization of the pharmaceutical composition according to Claim 21 wherein for gas exchange non-permeable packaging is Al/Al blister, Al-polychloro-3-fluoroethylene homopolymer/PVC laminate blister or bottle.
24. The method of stabilization of the pharmaceutical composition according to Claim 23 wherein for gas exchange non-permeable packaging is the Al/Al blister.
25. The method of stabilization of the pharmaceutical composition according to Claim 21 wherein an inert gas is nitrogen or argon.
26. The method of stabilization of the pharmaceutical composition according to Claim 25 wherein the inert gas is nitrogen.
27. The method of stabilization of the pharmaceutical composition according to Claim 21 wherein the pharmaceutical formulation is prepared in the form of tablets, orally dispersible pharmaceutical formulations, capsules, pellets or granulate.

28. A method of stabilization of a pharmaceutical formulation comprising an amorphous active substance and pharmaceutically acceptable excipients wherein a pharmaceutical formulation is stored in an inert atmosphere.
29. The method of stabilization of the pharmaceutical formulation according to Claim 28 wherein the amorphous active substance is atorvastatin calcium.
30. The method of stabilization of the pharmaceutical formulation according to Claim 28 wherein the gas for maintenance of an inert atmosphere is nitrogen or argon.
31. The method of stabilization of the pharmaceutical formulation according to Claim 30 wherein the gas for maintenance of an inert atmosphere is nitrogen.
32. The method of stabilization of the pharmaceutical formulation according to Claim 28 which is packed into for gas non-permeable packaging such as Al/Al blister, Al-polychloro-3-fluoroethylene homopolymer/PVC laminate blister or bottle.
33. The method of stabilization of the pharmaceutical formulation according to Claim 32 wherein for gas non-permeable packaging is the Al/Al blister.
34. The method of stabilization of the pharmaceutical formulation according to Claim 28 which is prepared in the form of tablets, orally dispersible pharmaceutical formulations, capsules, pellets or granulate.
35. A method of stabilization of an amorphous active substance wherein an amorphous substance is stored in an inert atmosphere.
36. The method of stabilization of the amorphous active substance according to Claim 35 wherein the amorphous active substance is atorvastatin calcium.

37. The method of stabilization of the amorphous active substance according to Claim 35 wherein the gas for maintenance of an inert atmosphere is nitrogen or argon.
38. The method of stabilization of the amorphous active substance according to Claim 37 wherein the gas for maintenance of an inert atmosphere is nitrogen.
39. The method of stabilization of the amorphous active substance according to Claim 35 wherein the active substance is packed into for gas non-permeable packaging such as metal container, glass container, for gas non-permeable plastic bag or for gas non-permeable plastic container.
40. The method of stabilization of the amorphous active substance according to Claim 39 wherein for gas exchange non-permeable packaging is for gas non-permeable plastic bag.
41. The stable pharmaceutical composition comprising the pharmaceutical formulation with the amorphous active substance which is prepared by the process according to Claims 21 to 27.
42. The stable pharmaceutical formulation comprising the amorphous active substance and pharmaceutically acceptable excipients which is prepared by the process according to Claims 28 to 34.
43. The stable amorphous active substance which is prepared by the process according to Claims 35 to 40.
44. The stable pharmaceutical composition according to Claim 1 is useful in treatment of hypercholesterolemia and hyperlipidemia.
45. The stable pharmaceutical formulation according to Claim 8 is useful in the treatment of hypercholesterolemia and hyperlipidemia.

46. The stable amorphous active substance according to Claim 15 is useful in the treatment of hypercholesterolemia and hyperlipidemia.